The EVI1 oncogene at human chr 3q26 is rearranged and/or overexpressed in a subset of acute myeloid leukemias and myelodysplasias. The EVI1 protein is a 135 kDa transcriptional regulator with DNA-binding zinc finger domains. Here we provide a critical review of the current state of research into the molecular mechanisms by which this gene plays a role in myeloid malignancies. The major pertinent cellular effects are blocking myeloid differentiation and preventing cellular apoptosis, and several potential mechanisms for these phenomena have been identified. Evidence supports a role for EVI1 in inducing cellular quiescence, and this may contribute to the resistance to chemotherapy seen in patients with neoplasms that overexpress EVI1. Another isoform, MDS1-EVI1 (or PRDM3), encoded by the same locus as EVI1, harbors an N-terminal histone methyltransferase(HMT) domain; experimental findings indicate that this protein and its HMT activity are critical for the progression of a subset of AMLs, and this provides a potential target for therapeutic intervention.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bcmd.2014.01.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MECOM Locus classical transcript isoforms affect tumor immune microenvironment and different targets in ovarian cancer.
J Ovarian Res
October 2024
Department of Radiotherapy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, 710061, PR China.
The MECOM locus is a gene frequently amplified in high-grade serous ovarian carcinoma (HGSOC). Nevertheless, the body of research examining the associations among MECOM transcripts, patient prognosis, and their role in modulating the tumor immune microenvironment (TIME) remains sparse, particularly in large cohorts. This study assessed the expression of MECOM transcripts in 352 HGSOC patients and 88 normal ovarian tissues from the combined GTEx/TCGA database.
View Article and Find Full Text PDF[The role and regulation of EVI1 in normal hematopoiesis and hematopoietic malignancies].
Rinsho Ketsueki
October 2024
Department of Cell Therapy & Transplantation Medicine, The University of Tokyo Hospital.
EVI1 is a zinc finger transcription factor encoded by the MECOM locus and is essential for the development and maintenance of hematopoietic stem cells. However, overexpression of EVI1 in various myeloid malignancies is associated with aggressive clinical behavior and poor outcome. The locus encodes multiple isoforms that are differentially acting and independently regulated.
View Article and Find Full Text PDFEfficient generation of human NOTCH ligand-expressing haemogenic endothelial cells as infrastructure for in vitro haematopoiesis and lymphopoiesis.
Nat Commun
September 2024
Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, VIC, Australia.
Article Synopsis
- The study reveals a method to create human haemogenic DLL4+ arterial endothelial cells (AECs) from pluripotent stem cells, essential for forming blood cells during embryonic development.* -
- Using single-cell RNA sequencing, researchers tracked the development of blood cell types in human embryos, identifying key pre-haematopoietic stem cell genes along the way.* -
- The research shows that IL7 influences the decision between T cells and innate lymphoid cells and establishes a pathway for RAG1+ lymphoid precursors to develop into natural killer cells, offering insights into blood system development.*
CRISPR-Cas9-mediated deletion enhancer of MECOM play a tumor suppressor role in ovarian cancer.
Funct Integr Genomics
July 2024
Department of Gynecology and Obstetrics, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong, 226001, China.
MDS1 and EVI1 complex locus (MECOM), a transcription factor encoding several variants, has been implicated in progression of ovarian cancer. The function of regulatory regions in regulating MECOM expression in ovarian cancer is not fully understood. In this study, MECOM expression was evaluated in ovarian cancer cell lines treated with bromodomain and extraterminal (BET) inhibitor JQ-1.
View Article and Find Full Text PDFOrthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML.
Nat Commun
June 2024
Department of Medicine and Surgery, University of Parma, Parma, Italy.
Article Synopsis
- The EVI1 gene is linked to a particularly aggressive form of acute myeloid leukemia (AML) characterized by abnormalities on chromosome 3q26.
- Selective and pan-histone deacetylase inhibitors (HDACis) have been identified as effective treatments for this type of leukemia by repressing EVI1 expression.
- The study suggests that the PA2G4 protein plays a key role in EVI1-related leukemia, and targeting PA2G4 could enhance the effects of HDACis, highlighting the potential for combination therapies in patients with 3q26 AML.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!